Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6768724 | 0.93 | ALDH1A1 (0.54) | ALDH1A1MEN1KMT2ATSHRCHRNB2 | |
| SCHEMBL6768874 | 0.93 | KMT2A (0.56) | ALDH1A1MEN1KMT2ATSHRCHRNB2 | |
| SCHEMBL6769824 | 0.92 | MEN1 (0.58) | ALDH1A1MEN1KMT2ATSHRCYP3A4 | |
| SCHEMBL6771057 | 0.92 | MEN1 (0.59) | ALDH1A1MEN1KMT2ATSHRCYP3A4 | |
| SCHEMBL6768950 | 0.91 | KMT2A (0.52) | ALDH1A1MEN1KMT2ATSHRKDM4E | |
| SCHEMBL6770885 | 0.91 | KMT2A (0.54) | ALDH1A1MEN1KMT2ATSHRCYP3A4 | |
| SCHEMBL6768765 | 0.90 | ALDH1A1 (0.57) | ALDH1A1MEN1KMT2ATSHRKDM4E | |
| SCHEMBL6770001 | 0.90 | MEN1 (0.53) | ALDH1A1MEN1KMT2ATSHRCHRNB2 | |
| SCHEMBL6769167 | 0.90 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2ATSHRKDM4E | |
| SCHEMBL6765540 | 0.89 | MAPT (0.52) | ALDH1A1MEN1KMT2ATSHRCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677336-B2 | PARTIAL FATTY ACID OXIDATION INHIBITORS; PROTECT SKELETAL MUSCLES AGAINST DAMAGE RESULTING FROM TRAUMA OR SYSTEMIC DISEASES, TREAT SHOCK CONDITIONS, PRESERVE DONOR TISSUE AND ORGANS USED IN TRANSPLANTS | CV THERAPEUTICS, INC. | 2004-01-13 | — | — | US | claimed |
| EP-1259493-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2002-11-27 | — | — | EP | claimed |
| US-20020016463-A1 | Substituted piperazine compounds | CV THERAPEUTICS, INC. | 2002-02-07 | — | — | US | claimed |
| WO-2001062744-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2001-08-30 | — | — | WO | claimed |
| US-6677336-B2 | PARTIAL FATTY ACID OXIDATION INHIBITORS; PROTECT SKELETAL MUSCLES AGAINST DAMAGE RESULTING FROM TRAUMA OR SYSTEMIC DISEASES, TREAT SHOCK CONDITIONS, PRESERVE DONOR TISSUE AND ORGANS USED IN TRANSPLANTS | CV THERAPEUTICS, INC. | 2004-01-13 | — | — | US | disclosed |
| US-20020016463-A1 | Substituted piperazine compounds | CV THERAPEUTICS, INC. | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016463-A1 | Substituted piperazine compounds | ATP2A1, CPT1B, TNNC1 | ALDH1A1 35/4885MEN1 4696/4885KMT2A 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.